SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025.
Read more at globenewswire.comNkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
Provided By GlobeNewswire – Last update: